Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
Condition(s):Chronic Myelogenous LeukemiaLast Updated:February 29, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Chronic Myelogenous LeukemiaLast Updated:February 29, 2024Active, not recruiting
Condition(s):Pigmented Villonodular Synovitis; Diffuse-type Giant Cell Tumor; Tenosynovial Giant Cell TumorLast Updated:January 24, 2024Active, not recruiting
Condition(s):Gynecologic Cancer; Gynecologic Neoplasms; Peritoneal Carcinomatosis; Peritoneal Neoplasms; Ovarian Cancer; Ovarian Neoplasms; Colorectal Cancer; Colorectal Neoplasms; Appendiceal Cancer; Appendiceal NeoplasmsLast Updated:March 15, 2024Recruiting
Condition(s):Chronic Myeloid LeukemiaLast Updated:December 11, 2023Active, not recruiting
Condition(s):Gastrointestinal CancerLast Updated:August 2, 2012Withdrawn
Condition(s):CML; Philadelphia Chromosome Positive (Ph+); Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough LevelsLast Updated:May 20, 2021Terminated
Condition(s):Chronic Myeloid LeukemiaLast Updated:May 1, 2019Completed
Condition(s):Philadelphia Chromsome Positive Acute Lymphoblastic LeukemiaLast Updated:July 30, 2020Completed
Condition(s):GIST; Metastatic DiseaseLast Updated:March 15, 2017Terminated
Condition(s):Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaLast Updated:December 9, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.